Role of sirtuin 6 in the protection of liver from the alcohol-induced injury

Sirtuin 6在保护肝脏免受酒精损伤中的作用

基本信息

项目摘要

Excessive alcohol consumption is a major risk factor for alcoholic liver disease (ALD), which manifests a spectrum of liver disorders including steatosis, steatohepatitis, fibrosis, cirrhosis, and even hepatocellular carcinoma. Alcohol related liver cirrhosis accounted for 0.9% of all global deaths and 47.9% of liver cirrhosis mortalities in 2010. The statistical numbers highlight the significance of alcohol effects on the liver pathology. However, the underlying mechanisms are still elusive and therapeutic treatments are lacking. To better understand the molecular mechanisms of ALD and identify potential drug targets, this principal investigator (PI) is investigating a critical epigenetic regulator, sirtuin 6 (Sirt6), an NAD-dependent histone deacetylase, which has been implicated in metabolism and inflammation. Sirt6 systemic knockout mice suffer chronic inflammation in multiple organs including the liver and develop progressive hepatic fibrosis. The PI's preliminary study has revealed that knockout of the Sirt6 gene in the liver significantly worsens the alcohol-induced liver injury with elevated levels of serum aspartate aminotransferase and increased expression of fibrosis markers, suggesting that Sirt6 is involved in ALD. We hypothesize that Sirt6 functions as a safeguard against the alcohol- induced liver damage. To test this hypothesis, the PI proposes to carry out the following specific aims: 1) Define the role of Sirt6 in the development of ALD; 2) Explore a novel Sirt6 pathway in the protection against the alcohol-induced liver injury. Overall, the proposed research addresses an important problem in the ALD field. Better understanding of the role of Sirt6 in ALD is expected to have significant implications for the development of prevention and treatment of this serious disease.
过量饮酒是酒精性肝病(ALD)的主要危险因素, 表现出一系列肝脏疾病,包括脂肪变性、脂肪性肝炎、纤维化、肝硬化, 甚至肝细胞癌。酒精性肝硬化占所有肝硬化的0.9%, 2010年全球死亡人数和肝硬化死亡人数的47.9%。统计数字显示, 酒精对肝脏病理学影响的意义。然而,潜在的机制 仍然难以捉摸,缺乏治疗方法。为了更好地理解 ALD的机制,并确定潜在的药物靶点,这主要研究者(PI)是 研究一种关键的表观遗传调节因子,sirtuin 6(Sirt 6),一种NAD依赖性组蛋白 脱乙酰酶,其与代谢和炎症有关。Sirt 6系统性 基因敲除小鼠在包括肝脏在内的多个器官中遭受慢性炎症, 进行性肝纤维化PI的初步研究表明,敲除Sirt 6 肝脏中的基因显著抑制了酒精诱导的肝损伤, 血清天冬氨酸转氨酶和纤维化标志物表达增加,表明 Sirt 6参与ALD。我们假设Sirt 6的功能是防止酒精- 导致肝损伤。为了检验这一假设,PI建议进行以下具体的 目的:1)明确Sirt 6在ALD发生发展中的作用; 2)探索一种新的Sirt 6通路, 对酒精性肝损伤的保护作用。总的来说,拟议的研究涉及 ALD领域的一个重要问题。希望能更好地了解Sirt 6在ALD中的作用 对预防和治疗这一严重疾病的发展具有重大意义, 疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

X Charlie Dong其他文献

X Charlie Dong的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('X Charlie Dong', 18)}}的其他基金

The pathophysiological function of PNPLA3-148M variant in alcohol-induced liver injury
PNPLA3-148M变异在酒精性肝损伤中的病理生理作用
  • 批准号:
    10366395
  • 财政年份:
    2022
  • 资助金额:
    $ 22.43万
  • 项目类别:
Role of SIRT6 in the pancreatic beta cell aging
SIRT6在胰腺β细胞衰老中的作用
  • 批准号:
    10371337
  • 财政年份:
    2022
  • 资助金额:
    $ 22.43万
  • 项目类别:
Role of SIRT6 in the pancreatic beta cell aging
SIRT6在胰腺β细胞衰老中的作用
  • 批准号:
    10641670
  • 财政年份:
    2022
  • 资助金额:
    $ 22.43万
  • 项目类别:
The pathophysiological function of PNPLA3-148M variant in alcohol-induced liver injury
PNPLA3-148M变异在酒精性肝损伤中的病理生理作用
  • 批准号:
    10613405
  • 财政年份:
    2022
  • 资助金额:
    $ 22.43万
  • 项目类别:
Role of ATG14 in the regulation of hepatic function
ATG14在肝功能调节中的作用
  • 批准号:
    10596539
  • 财政年份:
    2020
  • 资助金额:
    $ 22.43万
  • 项目类别:
Role of ATG14 in the regulation of hepatic function
ATG14在肝功能调节中的作用
  • 批准号:
    10371047
  • 财政年份:
    2020
  • 资助金额:
    $ 22.43万
  • 项目类别:
Epigenetic regulation in liver fibrosis
肝纤维化的表观遗传调控
  • 批准号:
    10640141
  • 财政年份:
    2020
  • 资助金额:
    $ 22.43万
  • 项目类别:
Epigenetic regulation in liver fibrosis
肝纤维化的表观遗传调控
  • 批准号:
    10172893
  • 财政年份:
    2020
  • 资助金额:
    $ 22.43万
  • 项目类别:
Epigenetic regulation in liver fibrosis
肝纤维化的表观遗传调控
  • 批准号:
    10428589
  • 财政年份:
    2020
  • 资助金额:
    $ 22.43万
  • 项目类别:
Sestrin3 in the pathogenesis of alcoholic and non-alcoholic fatty liver disease
Sestrin3 在酒精性和非酒精性脂肪肝发病机制中的作用
  • 批准号:
    9303199
  • 财政年份:
    2016
  • 资助金额:
    $ 22.43万
  • 项目类别:

相似海外基金

GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
GPR35:作为非酒精性脂肪肝疾病潜在治疗策略的作用和激动机制
  • 批准号:
    MR/X008827/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.43万
  • 项目类别:
    Research Grant
Perfluoroalkyl substances and non-alcoholic fatty liver disease in children: Leveraging magnetic resonance imaging to unravel potential mechanisms and exposure mixture effects
全氟烷基物质与儿童非酒精性脂肪肝:利用磁共振成像揭示潜在机制和暴露混合物效应
  • 批准号:
    10646759
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Development of Early Diagnostic Markers for Non-Alcoholic Fatty Liver Disease (NAFLD) and Investigation of Inflammatory Mechanisms of NAFLD
非酒精性脂肪性肝病(NAFLD)早期诊断标志物的开发及NAFLD炎症机制的研究
  • 批准号:
    23K07466
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Bacteriotherapy to treat non-alcoholic fatty liver disease
细菌疗法治疗非酒精性脂肪肝
  • 批准号:
    2893992
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
    Studentship
Investigating folliculin as a regulator of VLDL-TG secretion in non-alcoholic fatty liver disease and steatohepatitis
研究卵泡素作为非酒精性脂肪肝和脂肪性肝炎中 VLDL-TG 分​​泌的调节剂
  • 批准号:
    10679361
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
The Gut-Liver Axis in HIV-Related Non-Alcoholic Fatty Liver Disease
HIV 相关非酒精性脂肪肝中的肠肝轴
  • 批准号:
    10762284
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults
西班牙裔/拉丁裔成人饮食、代谢和非酒精性脂肪肝的流行病学
  • 批准号:
    10735454
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Elucidation of molecular mechanisms of SBP1-based regulation of non-alcoholic fatty liver development/progression
阐明基于 SBP1 调节非酒精性脂肪肝发生/进展的分子机制
  • 批准号:
    23K10862
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver Disease
Them1 治疗非酒精性脂肪肝的抑制剂
  • 批准号:
    10666090
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
Uncovering the role of GPR75 as an activator of fatty acid transporters in non-alcoholic fatty liver disease (NAFLD)
揭示 GPR75 作为脂肪酸转运蛋白激活剂在非酒精性脂肪性肝病 (NAFLD) 中的作用
  • 批准号:
    10666762
  • 财政年份:
    2023
  • 资助金额:
    $ 22.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了